Patient clustering by serum inflammatory mediators stratifies early disease-modifying antirheumatic drug-naïve rheumatoid arthritis and reveals distinct pathobiological signatures: a prospective observational cohort
Baseline serum inflammatory mediator profiles can stratify DMARD-naive patients with early RA into subgroups with distinct pathobiological mechanisms. These subgroup-specific signatures, including those of the IL-6-driven pathway, offer a basis for developing biomarker-guided therapeutic strategies.
Authors
- Hiroki Hill Kobayashi (ORCID: https://orcid.org/0000-0002-9674-0374)
- Michinori Ishitoku
- Genki Kidoguchi (ORCID: https://orcid.org/0009-0001-0558-8814)
- Sho Mokuda (ORCID: https://orcid.org/0000-0002-8529-1016)
- Tomohiro Sugimoto (ORCID: https://orcid.org/0000-0002-0968-9081)
- Yusuke Yoshida (ORCID: https://orcid.org/0000-0002-0774-0509)
- Naoya Oka (ORCID: https://orcid.org/0000-0001-8894-6535)
- Shintaro Hirata (ORCID: https://orcid.org/0000-0002-2474-9943)
- Yohei Hosokawa
Institutions
- Hiroshima University Hospital (JP)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-08-20
- DOI
- https://doi.org/10.55563/clinexprheumatol/bx6ql2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00